Objective:

To develop a novel approach for treating corneal injuries using genetically engineered bacteria that deliver anti-inflammatory therapy directly to the ocular surface.

Approach:

Key Findings:

• IL-10–producing bacteria significantly accelerated epithelial wound closure compared to controls.
• The engineered bacteria reduced local inflammation at the site of injury.
• Colonizing microbes could provide ongoing release of anti-inflammatory agents, unlike traditional eye drops.

Interpretation:

The findings suggest that the ocular microbiome can be utilized as a 'live biotherapeutic' for sustained delivery of therapeutic molecules, potentially transforming treatment for various ocular surface disorders.

Limitations:

• The research is currently at a preclinical stage and has not yet been tested in humans.
• Further studies are needed to evaluate safety and efficacy in human subjects.

Conclusion:

If successful in human trials, engineered ocular microbes could offer a new class of living therapeutics for managing ocular diseases requiring sustained local therapy.

Sources:

• Cell Reports
Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.